← All indications
Chikungunya Fever
An acute infection caused by a mosquito-borne alphavirus CHIKUNGUNYA VIRUS characterized by RASH; FEVER; JOINT PAINS; CONJUNCTIVITIS; MENINGOENCEPHALITIS; LYMPHOPENIA; and THROMBOCYTOPENIA.
Drugs by status
Approved for this indication (1)
Phase 4 trials (1)
Phase 3 trials (4)
Phase 2 trials (9)
Phase 1 trials (6)
Other trials (4)
Organizations
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (24)
- Biofabri, S.L
- PaxVax, Inc.
- SRI International
- Themis Bioscience GmbH
- The EMMES Corporation
- FHI 360
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- United States Army
- Medical University of Graz
- Centre Hospitalier Universitaire de Pointe-a-Pitre
- University of Puerto Rico
- University of Rostock
- University of Vienna
- Celerion
- Puerto Rico Clinical and Translational Reserach Consortium
- University Hospital Pointe-a-Pitre, Guadeloupe
- GHESKIO, Haiti
- Envigo Pharma Consulting Limited
- Assign Clinical Research GmbH
- ABF Pharmaceutical Services GmbH
- Batavia Biosciences
- Leidos
- University of the French West Indies and French Guiana
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (1)